Acquired GH resistance together with reduced skeletal muscle mass are found in patients with increased protein catabolism due, for example, to sepsis, trauma, or major surgery. Both administration of glutamine-containing parenteral nutrition and GH treatment have been found to diminish this catabolism. The effects of GH are mediated in part by insulin-like growth factor I (IGF-I) that is produced in the liver and locally in GH target tissues. The aim of this study was to investigate the effect of GH treatment on expression of the IGF-I gene and GH receptor (GHR) gene in skeletal muscle after major surgery. A new quantitative RT-PCR-based assay was established to measure IGF-I gene expression.
men), who were given glutamine-enriched total parenteral nutrition but no GH. A muscle biopsy was taken from the lateral portion of the quadriceps femoris muscle preoperatively (day 0) after induction of anesthesia. A second biopsy was taken under local anesthesia on postoperative day 3. Total ribonucleic acid (RNA) was extracted from the muscle biopsies, and IGF-I messenger RNA (mRNA) and GHR mRNA were measured by competitive quantitative RT-PCR assays. IGF-I mRNA and GHR mRNA levels were related to the expression of a housekeeping gene (cyclophilin). In the control group, IGF-I mRNA levels decreased from 1505 Ϯ 265 (mean Ϯ SEM) transcripts/ cpm cyclophilin on day 0 to 828 Ϯ 172 on day 3 (P Ͻ 0.05). In contrast, IGF-I mRNA levels did not change in the GH-treated group (1188 Ϯ 400 transcripts/cpm cyclophilin on day 0 vs. 1089 Ϯ 342 transcripts/ cpm cyclophilin on day 3). No statistically significant changes were seen in GHR expression.
We conclude that administration of GH prevents the reduction in IGF-I gene expression in skeletal muscle after abdominal surgery. (J Clin Endocrinol Metab 83: 1566 -1572, 1998) I NSULIN-LIKE growth factor I (IGF-I) is one of the major effectors of GH action. IGF-I levels in serum are believed to originate mostly from the liver; however, the growthpromoting actions of GH are due at least partly to a direct action of GH in its various target tissues. Thus, the serum concentration of IGF-I may not be an accurate indicator of the effects of GH in some tissues. For example, GH administered by local injection in the growth plate stimulates longitudinal bone growth by increasing the local production of IGF-I without increasing circulating IGF-I levels in the blood (1, 2) .
Acquired GH resistance is seen in many different disease states (for review, see Ref. 3) . The protein wasting seen in catabolic states is a well recognized clinical problem, for example in patients undergoing major surgery. When prolonged, protein wasting increases the risk of complications associated with immunosuppression and muscle weakness (3) . Patients undergoing elective abdominal surgery are suitable for studies of acquired GH resistance because the onset of the GH resistance is abrupt and defined. GH therapy has been found to improve nitrogen balance in this group of patients (4), but the mechanisms behind this effect are unknown. We have recently developed a quantitative RT-PCR (Q-RT-PCR) assay (5) that enables us to measure changes in GH receptor (GHR) gene expression in tissue samples obtained by needle biopsies. We now report a new Q-RT-PCR assay for measurement of IGF-I messenger ribonucleic acid (mRNA) in human tissues. In the present study this new assay has been used to determine the effect of GH treatment on IGF-I gene expression in skeletal muscle after major surgery.
Subjects and Methods

Subjects and samples
Patients without demonstrable systemic illness, scheduled for elective colorectal surgery, were included in the study. The characteristics of the patients and the surgical procedures are shown in Table 1 . The patients were given standard postoperative parenteral nutrition containing 0.15 g nitrogen/kg⅐day and including 0.28 g glutamine/kg⅐day. Energy was provided as equal amounts of glucose and fat (10% glucose and 20% Intralipid; Pharmacia & Upjohn, Stockholm, Sweden) given at 1.2 times the calculated caloric need according to the Harris-Benedict formula. During the day of operation, 75% of this nutritional regimen was given. One group of patients (n ϭ 5) was given daily sc injections of recombinant human GH (0.3 IU/kg⅐day; Genotropin, Pharmacia & Upjohn), whereas the other group served as controls (n ϭ 8). The study was randomized, but not blinded.
After induction of anesthesia, a muscle biopsy was taken from the lateral portion of the quadriceps femoris muscle, using the percutaneous technique. The muscle was carefully dissected to remove all visible fat and connective tissue. A second muscle biopsy was taken on postoperative day 3 under local anesthesia of the skin and fascia only. Portions (30 -40 mg wet weight) were frozen in liquid nitrogen and stored at Ϫ80 C until analyzed. Total RNA was isolated using guanidium-thiocyanatephenol-chloroform extraction, as described by Chomczynski and Sacchi (6) . At the time of biopsy and on postoperative days 1 and 2, venous blood samples were taken for determination of IGF-I and IGF-binding protein 3 (IGFBP-3).
The study was approved by the ethical committees of Goteborg University (Goteborg, Sweden) and the Karolinska Institute (Stockholm, Sweden). The procedure of the study, possible discomfort, and risks involved were explained to the patients, and their informed consent was obtained before participation in the study.
Q-RT-PCR for IGF-I gene expression
Primers. The primers were designed to amplify a fragment of the IGF-I complementary DNA (cDNA) that is present in all splice variants of the IGF-I mRNA (Fig. 1a) . Primers were purchased from KEBO Lab (Spanga, Sweden), except for the biotinylated primers, which were purchased from Scandinavian Gene Synthesis AB (Koping, Sweden). The sequences of the primers are listed in Table 2 , and their locations are shown in Fig. 1b .
Generation of synthetic RNA standard. A 182-bp fragment of the human IGF-I cDNA, corresponding to parts of exons 3 and 4 of the IGF-I gene, was amplified by RT-PCR from total RNA from IM-9 cells, using primers IGF BamHI and IGF PstI (15-s denaturation at 94 C, 15-s annealing at 57 C, and 30-s elongation at 72 C). The fragment was subcloned into pCRII (Invitrogen, San Diego, CA), generating pIGF-wt. The identity of the subcloned fragment was verified by DNA sequencing using PRISM Sequenase Terminator Double Stranded DNA Sequencing Kit (Applied Biosystems, Foster City, CA) and an ABI 373A automatic sequencer (Applied Biosystems). A point mutation (G to C) was introduced at nucleotide 450 (7) using PCR-based mutagenesis (8) . This mutation introduced a PleI/HinfI site and destroyed a Fnu4HI/BbvI restriction site. In brief, two overlapping fragments were produced with IGF-I cDNA as template in two separate PCR reactions, using primers IGF PstI and IGF mutG, and IGF mutC and IGF BamHI, respectively. The two , showing the localization of primers used in the study. As only exons 3 and 4 are present in all IGF-I mRNA transcripts, these were used as targets for the RT-PCR in the assay. In B, the letters correspond to primers specified in Table 2 : a, Bio-IGF and IGF PstI; b, IGF mutC; c, IGF mutG; d, IGF seq; and e, IGF BamHI. The X represents the variable nucleotide in the standard, and the Bio indicates that the primer is biotinylated. The vertical line represents the boundary between exons 3 and 4. Negative controls were always included during cDNA synthesis and PCR to confirm that there was no contamination.
Assay procedure
To minimize the risk of PCR contamination, specific steps of the assay were carried out in separate rooms for RNA preparation, pre-PCR, PCR, and post-PCR. The assay procedure is outlined in Fig. 2 . Samples of total RNA extracted from human tissues or synthetic IGF wt RNA (for the standard curve; 0.0156 -1.0 ϫ 10 6 transcripts/reaction) were mixed with 10 5 molecules of synthetic IGF mut RNA. In addition, samples containing only 10 5 transcripts of mutated RNA were included as blanks. The samples were reverse transcribed into cDNA, and the PCR was carried out as described above, using primers Bio-IGF and IGF BamHI. For immobilization and purification of the PCR products, the PCR solution (20 L) was mixed with 40 L PBS buffer [0.14 mol NaCl/L, 0.01 mol sodium phosphate buffer/L (pH 7.4), and 0.1% Tween-20] and dispensed into streptavidin-coated microtiter plates (Streptavidin Covalent Strips, Wallac Oy, Turku, Finland) that were prewashed four times at room temperature with TENT buffer [40 mmol Tris-HCl/L (pH 8.8), 1 mmol ethylenediamine tetraacetate/L, 50 mmol NaCl/L, and 0.1% Tween-20] in an automated microtiter washer (Scanwasher, Skantron Instruments, Lier, Norway). The plates were sealed and incubated for 1.5 h with gentle agitation at 37 C and subsequently washed four times with TENT buffer. To obtain single-stranded DNA, the immobilized PCR products were denatured with 100 L 50 mmol NaOH/L plus 150 mmol NaCl/L twice for 5 min each time at room temperature, followed by four washes with TENT buffer. The ratio between the IGF wt and IGF mut sequences was determined by two separate minisequence reactions, in which the primer IGF seq, complementary to the sequence immediately 3Ј to the variable nucleotide, was extended with a radiolabeled nucleotide, either C for the IGF wt or G for the IGF mut sequence. The sequence reaction was carried out at 54 C for 10 min in PCR buffer [ The abundance of IGF-I transcripts was compared with the expression of a housekeeping gene, cyclophilin (9) , and IGF-I mRNA levels were expressed as IGF-I transcripts per cpm cyclophilin. RT-PCR of cyclophilin was carried out using primers B-CP1 and CP2 (Table 1) for 27 cycles (15-s denaturation at 94 C, 15-s annealing at 57 C, and 30-s elongation at 72 C). (Table 1) were used in the cyclophilin minisequence reaction.
Measurements of GHR mRNA
GHR mRNA was measured by a Q-RT-PCR-based assay similar to the assay for IGF-I mRNA described above (5).
GH-binding protein (GHBP) assay
Total GHBP was measured by a ligand-mediated immunofunctional assay, as previously described (10) . The detection range of the ligandmediated immunofunctional assay was 15.6 -1000 pmol/L. The intraassay coefficient of variation was 7.3%. All samples were analyzed in the same assay.
IGF-I assay
Plasma concentrations of IGF-I were measured by RIA (Nichols Institute Diagnostics, San Juan Capistrano, CA). IGF-I was separated from binding proteins using an acid-ethanol and alkaline precipitation step. At 352 g/L, the intraassay coefficient of variation was 4.8%, and the interassay coefficient of variation was 3.5%.
IGFBP-3 assay
Plasma levels of IGFBP-3 were measured by RIA (Nichols Institute Diagnostics). At 3.4 mg/L, the intraassay coefficient of variation was 4.2%, and the interassay coefficient of variation was 2.4%.
Statistical analysis
For evaluation of changes before (day 0) and after surgery (day 3), a Wilcoxon signed rank test was used. Changes were considered significant if P Ͻ 0.05. Data are presented as the mean Ϯ sem. The localization of the primers used in the assay is also shown (7, 9) . The asterisk indicates a mutated nucleotide, as described in Materials and Methods. Underlined sequences show those unrelated to the IGF-I gene, including a GC-clamp and restriction sites for PstI and BamHI.
Results
Assay performance
The assay reproducibility was determined by measurements of IGF-I mRNA in replicates of total RNA (50 ng) from human liver. The intraassay coefficient of variation varied between 11.3% (n ϭ 5) and 13.5% (n ϭ 8). IGF-I mRNA was measured in serial dilutions of total RNA extracted from human liver. In samples containing 25, 50, and 100 ng total RNA from the same liver sample, 2434, 2471, and 2432 IGF-I mRNA molecules/ng total RNA were detected, indicating that the assay is linear. The detection limit for the assay was 1.6 ϫ 10 4 molecules/reaction, as defined by Rodbard et al.
(11) to be the equivalent to the concentration corresponding to the mean absorbance of zero plus twice the sd.
IGF-I and GHR mRNA abundance in skeletal muscle biopsies
The IGF-I mRNA levels were measured in skeletal muscle before and 3 days after abdominal surgery in five patients given total parenteral nutrition (TPN), glutamine, and GH and in eight patients given TPN and glutamine only (control group). In the control group, IGF-I mRNA levels decreased after surgery (1505 Ϯ 265 vs. 828 Ϯ 172 transcripts/cpm cyclophilin; P Ͻ 0.05; Fig. 3a) . In contrast, IGF-I expression FIG. 2. Schematic overview of the procedure for the Q-RT-PCR assay for IGF-I mRNA quantification. A sample of total RNA, containing the target mRNA, is mixed with a fixed amount of the mutated internal standard (IGF-mut), reverse transcribed, and amplified by PCR. The use of one biotinylated primer allows purification of single-stranded PCR products on streptavidin-coated microtiter wells. The ratio between mutated and IGF-I wt mRNA transcripts was determined by two separate minisequence reactions, in which the primer, complementary to the sequence immediately 3Ј to the variable nucleotide, was extended with a single radiolabeled nucleotide complementary to either the wt or mut PCR product. A standard curve was generated by mixing serial dilutions of the synthetic IGF-wt RNA with fixed amounts of synthetic IGF-mut RNA.
did not change after surgery in the GH-treated group (1188 Ϯ 400 vs. 1089 Ϯ 342 transcripts/cpm cyclophilin; P ϭ 0.81; Fig.  3b ). There were no statistically significant changes in GHR gene expression in the two groups [199 Ϯ 34.1 vs. 184 Ϯ 49.1 transcripts/cpm cyclophilin (Fig 3c) and 125 Ϯ 19.9 vs. 230 Ϯ 64.0 transcripts/cpm cyclophilin (Fig 3d) for the controls and the GH-treated subjects, respectively].
Effects of GH on plasma levels of IGF-I, IGFBP-3, and GHBP
Plasma levels of IGF-I and IGFBP-3 were measured before surgery and on days 1, 2, and 3 after surgery in all patients. For statistical analysis, the levels on day 0 were compared with the levels on day 3. In the control group, plasma IGF-I levels were unchanged (128 Ϯ 26.2 vs. 140 Ϯ 30.8 g/L; Fig.  4a) , whereas there was a significant decrease in plasma IG-FBP-3 (2.5 Ϯ 0.27 vs. 2.0 Ϯ 0.22 mg/L; P Ͻ 0.05; Fig. 4c ). In the GH-treated group there was a nonsignificant (P ϭ 0.063) increase in plasma levels of both IGF-I (139 Ϯ 33.7 vs. 381 Ϯ 60.0 g/L; Fig. 4b ) and IGFBP-3 (2.0 Ϯ 0.28 vs. 2.8 Ϯ 0.34 mg/L; Fig. 4d ). Plasma GHBP levels decreased from day 0 to day 3 in all patients for whom samples were available for analysis; unfortunately, only three patients in the GH-treated group and seven patients in the control group were available for analysis (data not shown).
Discussion
Marked catabolism and muscle wasting are well recognized problems in patients with severe systemic illness, such as sepsis, and after major trauma or surgery. The mechanisms behind the increased catabolism in such patients are not known; however, several studies in both animals and humans indicate that changes in the GH/IGF-I axis may be involved (for review, see Ref.
3). Treatment with high doses of GH has been shown to preserve a positive nitrogen balance after surgery (4, 12, 13) , as has addition of glutamine to parenteral nutrition (14) .
In this study we examined the effects of GH administration on expression of the GHR gene and the IGF-I gene in patients undergoing abdominal surgery. We demonstrated that although IGF-I levels in plasma were unchanged after abdominal surgery, there was a significant decrease in IGF-I mRNA levels in skeletal muscle 3 days after surgery. These changes were reversed by once daily sc injection of GH.
The IGF-I level in plasma/serum has been proposed as a good indicator of GH activity. However, circulating IGF-I, most of which is believed to originate from the liver, may not reflect the level of IGF-I produced in peripheral target tissues in response to GH. Furthermore, serum concentrations of IGF-I are also influenced by nutrition and body composition. This is a particular problem in adults with GH deficiency, in whom there is a large overlap between patients and controls (15) despite great abnormalities in body composition as a result of GH deficiency (16) . In the present study, IGF-I levels in plasma were unchanged in the control group, whereas IGF-I gene expression in skeletal muscle decreased significantly. GH treatment increased IGF-I levels in plasma, whereas IGF-I expression was unchanged in skeletal muscle. The differential regulation of plasma IGF-I and IGF-I mRNA in skeletal muscle together with the assumption that the liver is the major producer of plasma IGF-I suggest that the regulation of IGF-I gene expression is different in skeletal muscle and liver. This emphasizes the potential importance of this new Q-RT-PCR for IGF-I mRNA in studying the different effects of GH in various human tissues and organs. In acquired GH resistance and in some short children, the effects of GH are less than expected, and we believe that measurements of IGF-I and GHR mRNA expression in different tissues might help in the understanding of some of the mechanisms involved.
There was no change in GHR mRNA gene expression after surgery in the control group, in contrast to our previous findings (5) . GHBP levels decreased in all patients for whom samples were available for analysis. In our previous study we also demonstrated that both GHR mRNA in skeletal muscle and plasma levels of GHBP fell in parallel after abdominal surgery (5) . However, the present protocol is different from that used previously, in that all patients received glutamine in the TPN. This might have affected GHR gene expression, although further studies are necessary to confirm this hypothesis. GH appeared to have a minor, if any, effect on GHR expression in skeletal muscle. This is consistent with the results from previous studies, in which minor changes in GHBP levels occurred after the start of GH treatment in both children (17) and adults (18) with GHD. However, it should be noted that adults with GHD are a much more homogeneous group than children with GHD, in that they have very low levels of GH secretion, if any. The fact that there was no dramatic change in GHBP in adults with GHD further strengthens the argument that GH has little or no role in the regulation of GHBP.
PCR techniques have been used to quantify gene expression in different tissues. The technique is so sensitive that extreme care must be taken to prevent contamination of the sample by previously amplified DNA material. Another problem is that when comparing the abundance of different mRNAs, the efficacy of amplification can vary, which applies both to the RT step and the PCR amplification. By using an internal standard, it is possible to compensate for differences in the efficacy of the cDNA synthesis and the PCR reaction, which could otherwise be a source of considerable intersample variation in RT-PCR assays. The advantage of using an internal standard that differs from the wt mRNA by only one base is that the same primer pair can be used for amplification of both standard and sample. Furthermore, as the fragments differ only by one base, the efficacy of the amplification is similar. Both of these factors are important in excluding selective amplification of one fragment. The two fragments compete for amplification in the PCR reaction, and the ratio between the two is relative to the amount of RNA in the sample, independently of whether the PCR reaction is in the exponential or the plateau phase. As the concentration of the mutated fragment is known, the amount of IGF-I wt mRNA in the sample can be calculated from a standard curve.
In conclusion, we have demonstrated that although plasma IGF-I levels were unchanged after major surgery, there was a significant decrease in IGF-I gene expression in skeletal muscle. GH treatment prevented these changes in IGF-I gene expression and induced a clear trend for an increase in IGF-I and IGFBP-3 levels. The new Q-RT-PCR technique, with its high sensitivity, makes studies possible on small biopsy samples. It, therefore, opens new possibilities for performing dynamic studies on the action of GH and the sensitivities of various tissues to GH.
